Lilly to participate in TD Cowen's 46th Annual Health Care Conference [Accessibility Statement] Skip NavigationINDIANAPOLIS, Feb. 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026. Lucas Montarce, executive vice president and chief financial officer, will take part in a fireside chat at 3:10 p.m., Eastern time.A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to alleged violations of federal securities laws related to misleading statements about the efficacy of its drug setrusumab for Osteogenesis Imperfecta [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Ultragenyx to contact them directly to discuss their legal options [1]. - There is a deadline of April 6, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Ultragenyx [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Ultragenyx - The complaint alleges that Ultragenyx and its executives made false and misleading statements regarding the effects of setrusumab, creating a false impression of reliable information while downplaying risks associated with the Phase III Orbit study [4]. - Ultragenyx's optimism regarding the Phase III Orbit study's results was deemed misplaced, as the company failed to adequately disclose risks related to the study's Phase II results, which lacked a placebo control group [4]. Group 3: Stock Performance Impact - On July 9, 2025, Ultragenyx announced that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [5]. - Following a December 29, 2025 announcement that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock fell more than 42% [6][7].

Industry Overview - The U.S. pharmaceutical industry is projected to grow from $634.32 billion in 2024 to $883.97 billion by 2030, driven by strong momentum in customized medicine, which is expected to increase from $169.56 billion in 2024 to $307.04 billion by 2033, reflecting a compound annual growth rate (CAGR) of 6.82% from 2025 to 2033 [1][2] - Key drivers include improvements in next-generation sequencing, rising demand for tailored treatments, and favorable legal frameworks for drug development and diagnostics, although high development costs and a lack of clinical standards pose challenges [2] Policy Changes - Significant policy changes during President Donald Trump's second term include a 100% tariff on imported name-brand medications starting in 2025 and a "Build It Here" mandate to promote domestic production [3] - The implementation of Most-Favored-Nation pricing orders and the introduction of TrumpRx.gov aim to align American drug prices with those of other developed nations, emphasizing cost minimization and pharmaceutical self-reliance through expedited approval processes for generics and biosimilars [3] Market Risks and Opportunities - The Boston Consulting Group warns of a $350 billion global patent cliff as major medications like Keytruda and Eliquis lose exclusivity, although growth is anticipated through biologics, gene treatments, and AI-driven R&D [4] - Analysts predict increased mergers and acquisitions, stable credit conditions supported by substantial cash reserves, and ongoing innovation in the sector [4] M&A Activity and Future Outlook - Robust early-year M&A activity has been noted, with expectations for improved performance in 2026 for pharmaceutical and biotech companies, particularly in cardiometabolic, obesity, cardiovascular, and cancer sectors, as major patent cliffs approach in 2028 and 2029 [5] Stock Selection Methodology - The selection of pharmaceutical stocks is based on a forward PE ratio of 20 or less, with the top 7 stocks ranked by the number of hedge fund holders as of Q3 2025 [7] - Research indicates that imitating the top stock picks of leading hedge funds can lead to market outperformance, with a reported return of 427.7% since May 2014, surpassing benchmarks by 264 percentage points [8] Company Highlights - **Phibro Animal Health Corporation (NASDAQ:PAHC)**: - Number of Hedge Fund Holders: 23 - Forward PE Ratio: 17.28 - Recent fiscal second-quarter results showed a 21% increase in net sales to $373.9 million and a net income rise to $27.5 million, with adjusted EBITDA up 41% to $68.1 million and adjusted diluted EPS up 58% to $0.87 [10][12] - Full-year net sales estimates have been updated to $1.45 billion to $1.50 billion, with adjusted EBITDA projected at $245 million to $255 million [13] - **Collegium Pharmaceutical, Inc. (NASDAQ:COLL)**: - Number of Hedge Fund Holders: 27 - Forward PE Ratio: 6.13 - The company expects net product revenue for 2026 to range from $805 million to $825 million, with Jornay PM anticipated to generate net sales of at least $190 million to $200 million [15][17] - Adjusted EBITDA is projected to be between $455 million and $475 million, indicating strong profitability and effective cost control [17]

Group 1 - Brendan, a co-founder of 1200 Pharma, has a strong background in organic synthesis and experience in both pharmaceutical and biotech sectors [1] - 1200 Pharma received significant investment, amounting to eight figures, indicating strong market interest and potential for growth [1] - Brendan's investment focus is primarily on biotechnology stocks, suggesting a strategic alignment with industry trends [1] Group 2 - The current investment strategy includes a diversified portfolio with broad-based ETFs to mitigate volatility, indicating a cautious approach to market fluctuations [3] - ZTS is identified as a potential strong-buy opportunity at a target price of $105 per share, which would provide a substantial margin of safety for investors [3] - The strategy may involve selling cash-secured puts to achieve an attractive cost basis, reflecting a tactical approach to investment in ZTS [3]

Core Viewpoint - Acurx Pharmaceuticals is set to discuss its full year and fourth quarter 2025 financial results on March 13, 2026, and will provide a business update during the conference call [1]. Group 1: Financial Results Announcement - The conference call will take place at 8:00 am ET before U.S. financial markets open [1]. - David P. Luci, President and CEO, and Robert G. Shawah, CFO, will host the call to discuss the financial results [1]. Group 2: Product Development - Acurx's lead antibiotic candidate, Ibezapolstat, is preparing for international Phase 3 clinical trials aimed at treating C. difficile Infection (CDI) [1]. - Ibezapolstat is a novel, orally administered antibiotic classified as a Gram-Positive Selective Spectrum (GPSS®) antibacterial, representing a new class of DNA polymerase IIIC inhibitors [1]. - The company has received final advice from both EMA and FDA regarding the Phase 3 trials, confirming the study design, patient population, and endpoints [1]. Group 3: Regulatory Status - Ibezapolstat has been designated as a Qualified Infectious Disease Product (QIDP) by the FDA, making it eligible for incentives under the GAIN Act [1]. - The FDA granted "Fast Track" designation to Ibezapolstat for CDI treatment in January 2019 [1]. - The CDC has classified C. difficile as an urgent threat, underscoring the need for new antibiotics [1]. Group 4: Company Overview - Acurx Pharmaceuticals focuses on developing a new class of small molecule antibiotics targeting difficult-to-treat bacterial infections [1]. - The company's R&D pipeline includes antibiotic candidates aimed at Gram-positive bacteria, including CDI, MRSA, VRE, and drug-resistant Streptococcus pneumoniae [1].

Market Overview - The Uterine Fibroid Market was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033, growing at a CAGR of 7.63% from 2026 to 2033 [1][8]. Growth Drivers - The market is expanding due to the increased incidence of uterine fibroids among women of childbearing age, with approximately 70 to 80% of women experiencing fibroids by age 50 [2]. - Rising healthcare infrastructure in emerging markets and increased awareness regarding fibroid treatment options are also contributing to market growth [5]. Treatment Trends - There is a significant trend towards minimally invasive techniques for treating uterine fibroids, with adoption rates rising by over 60% in the past five years [4]. - Minimally invasive procedures are expected to grow at the fastest CAGR of 8.63% from 2026 to 2033, driven by advancements in technology and patient preference for less invasive options [11]. Market Segmentation - By Type: Submucosal Fibroids dominated with 36.24% in 2025, while Intramural Fibroids are expected to grow at the fastest CAGR of 8.20% from 2026 to 2033 [9][10]. - By Treatment Type: Surgical Procedures held 38.45% in 2025, with Minimally Invasive Procedures projected to grow at 8.63% CAGR [11]. - By Technology: Laparoscopic Surgery accounted for 36.58% in 2025, with MRI-Guided Focused Ultrasound expected to grow at 8.83% CAGR [12]. - By End-User: Hospitals & Clinics dominated with 47.49% in 2025, while Ambulatory Surgical Centers are expected to grow at 8.43% CAGR [13]. Regional Insights - The U.S. Uterine Fibroid Market was valued at USD 1.78 Billion in 2025 and is projected to reach USD 3.11 Billion by 2033, growing at a CAGR of 7.25% [14]. - North America is expected to hold a 45.32% market share in 2025, while Asia Pacific is anticipated to grow at the fastest CAGR from 2026 to 2033 [15]. Recent Developments - In January 2024, Pfizer Canada announced the availability of MYFEMBREE® for treating uterine fibroids and endometriosis [17]. - In September 2024, Theramex announced the first commercial sale of Yselty® in Germany, marking a new treatment option for women with moderate to severe symptoms of uterine fibroids [17].

Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]The logo of French drugmaker Sanofi is seen in Paris, France, January 9, 2026. REUTERS/Gonzalo Fuentes/File Photo [Purchase Licensing Rights, opens new tab]- Companies[Sanofi SA]Follow[Eli Lilly and Co]Follow[Merck KGaA]FollowShow more companiesFeb 16 (Reuters) - French drugmaker Sanofi [(SASY.PA), opens ...

Core Insights - Eli Lilly's Retevmo (selpercatinib) shows significant event-free survival benefits as an adjuvant therapy for early-stage RET fusion-positive lung cancer, meeting its primary endpoint in the Phase 3 LIBRETTO-432 trial [1] - The trial demonstrated a statistically significant improvement in event-free survival (EFS) compared to placebo, although overall survival results were still immature at the time of analysis [1] - The study reinforces the importance of genomic testing for patients diagnosed with early-stage lung cancer [1] Group 1: Clinical Trial Results - LIBRETTO-432 is the first randomized Phase 3 study evaluating a selective RET kinase inhibitor as adjuvant therapy in early-stage RET fusion-positive non-small cell lung cancer (NSCLC) [1] - The trial enrolled 151 patients, randomized 1:1 to receive either selpercatinib or placebo, with the primary endpoint being EFS assessed by investigators [1] - Secondary endpoints included overall survival, EFS assessed by blinded independent central review, and time to distant disease recurrence [1] Group 2: Patient Demographics and Disease Context - NSCLC accounts for approximately 85% of all lung cancer diagnoses in the U.S., with around 30% of patients presenting with stage IB-IIIA disease [1] - About 50% of NSCLC patients have actionable biomarkers, with RET fusions identified in 1-2% of all NSCLC cases [1] Group 3: Safety Profile - The overall safety profile of selpercatinib in LIBRETTO-432 was consistent with previous trials, with serious hepatic adverse reactions occurring in 3% of patients [2] - Increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were observed in 59% and 55% of patients, respectively [2] - Hypertension occurred in 41% of patients, with Grade 3 hypertension in 20% [2] Group 4: Future Directions - Detailed results from the LIBRETTO-432 trial will be presented at an upcoming medical congress and submitted for peer review [1] - The company aims to accelerate the use of genomic testing for all patients diagnosed with early-stage lung cancer based on these findings [1]

Core Insights - Immunic has successfully completed an oversubscribed private placement of up to $400 million, marking its transition from an R&D-focused organization to a commercial-stage entity [1] Funding and Financial Details - The private placement was led by existing investor BVF Partners, with participation from Avidity Partners, OrbiMed, Trails Edge Capital Partners, TCGX, Vivo Capital, and other institutional investors [1] - Under the terms of the private placement, Immunic will issue 229.1 million pre-funded warrants at a price of $0.873 per warrant, generating upfront proceeds of $200 million [4] - Investors will also receive warrants for an additional 229.1 million shares at the same price for the remaining $200 million, with expiration set for 30 days after the public release of Phase III ENSURE data or on February 17, 2031 [4] Clinical Development Plans - Proceeds from the placement will be used to complete ongoing Phase III ENSURE studies of vidofludimus calcium in relapsing multiple sclerosis (MS), with top-line results expected by the end of this year [2] - The company plans to submit a new drug application (NDA) in the US by mid-2027, targeting regulatory approval in 2028 [2] - Immunic also intends to launch a Phase III clinical program in primary progressive multiple sclerosis (PPMS) later this year, estimating that this trial will take approximately three-and-a-half to four years to complete [3] Strategic Leadership Changes - Immunic's co-founder and CEO Dr. Daniel Vitt will transition to a new executive role focused on scientific strategy and portfolio advancement, while the board will begin searching for a new CEO with expertise in MS commercialization [5]

Core Viewpoint - Goldman Sachs anticipates that European and emerging-market equities will outperform the U.S. stock market over the next decade, with the S&P 500 projected to return 6.5% annually compared to 7.5% for European stocks and 12.8% for emerging-market stocks [1][2]. European Equities - European stocks are expected to achieve a 7.5% annual return, driven by strong earnings growth, a high dividend yield of approximately 3%, and stock buybacks [2]. - The Vanguard FTSE Europe ETF tracks around 1,200 companies in Europe, with significant weight in financials (24%), industrials (19%), and healthcare (13%) [5]. - Over the past decade, the S&P 500 outperformed the Vanguard FTSE Europe ETF, returning 335% (15.8% annually) compared to 174% (10.5% annually) for the European ETF [5][6]. - Analysts believe that European stocks, trading at cheaper valuations, could outperform U.S. stocks due to the historical expense of U.S. equities and a projected decline in the U.S. dollar relative to the euro [6]. Emerging-Market Equities - Emerging-market stocks are projected to return 12.8% annually, bolstered by strong earnings growth in China and India [2]. - The Vanguard FTSE Emerging Markets ETF measures the performance of about 6,200 companies, with a focus on technology (29%), financials (21%), and consumer discretionary (12%) [9]. - The Vanguard FTSE Emerging Markets ETF returned 162% (10.1% annually) over the last decade, significantly lagging behind the S&P 500, which returned 335% [9][10]. - Analysts expect emerging-market stocks to outperform due to stronger earnings growth, higher dividend yields, and a weakening U.S. dollar against emerging-market currencies [10]. Investment Options - The Vanguard FTSE Europe ETF has a low expense ratio of 0.06%, making it a cost-effective option for investors seeking exposure to European equities [8]. - Similarly, the Vanguard FTSE Emerging Markets ETF also features a low expense ratio of 0.06%, which is significantly lower than the average expense ratio of 1.13% for similar funds [11].